Pharmaceuticals’ development was not really convincing despite the organic growth as profitability suffered and, in addition, Consumer Health was not a very good segment, like Animal Health. Only Crop Science generated good and profitable growth. As our estimates were packed with impairments and provisions linked to the Monsanto acquisition, Bayer’s figures beat our estimates and were slightly better than the consensus.
27 Feb 2019
Pharma's softening dynamics
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pharma's softening dynamics
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
27 Feb 2019 -
Author:
Martin Schnee -
Pages:
3
Pharmaceuticals’ development was not really convincing despite the organic growth as profitability suffered and, in addition, Consumer Health was not a very good segment, like Animal Health. Only Crop Science generated good and profitable growth. As our estimates were packed with impairments and provisions linked to the Monsanto acquisition, Bayer’s figures beat our estimates and were slightly better than the consensus.